Literature DB >> 16341488

Polidocanol at different concentrations for pleurodesis in rats.

Bahadir Cetin1, E Arzu Koçkaya, Can Atalay, M Turan Akay.   

Abstract

PURPOSE: We previously found that 0.5% polidocanol was more effective than tetracycline for pleurodesis in rats. Thus, we conducted the present study to evaluate the efficacy of different concentrations of polidocanol for pleurodesis in rats.
METHODS: We divided 54 albino Wistar rats into six groups. Groups 1, 2, and 3 were given isotonic saline, 35 mg/kg tetracycline, and 0.6 mg of diluted polidocanol, respectively, being the daily recommended dose for humans. Groups 4, 5, and 6 were given 0.5%, 1%, and 2% polidocanol, respectively. All solutions were given intrapleurally in a volume of 0.5 ml. We examined the rats for macroscopic pleural adhesions and compared the mean values of macroscopic scoring among the six groups.
RESULTS: The rats given polidocanol and tetracycline had significantly more adhesions than the control group, and polidocanol at concentrations of 0.5%, 1%, and 2% was more effective for pleurodesis than tetracycline. The diluted polidocanol was not more effective than tetracycline. There was no difference between the effects of the 0.5% and 1% concentrations, but the 2% polidocanol group had significantly more adhesions than the other groups.
CONCLUSIONS: Polidocanol at concentrations of 0.5%, 1%, and 2% was a more effective sclerosing agent than tetracycline for pleurodesis. While 2% polidocanol was the most efficient sclerosing agent, the daily maximum recommended dose of polidocanol for humans was not more effective than tetracycline.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16341488     DOI: 10.1007/s00595-005-3080-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  16 in total

1.  Intrapleural tetracycline for control of malignant pleural effusion: a preliminary report.

Authors:  R M Rubinson; H Bolooki
Journal:  South Med J       Date:  1972-07       Impact factor: 0.954

2.  Pleurodesis by autologous blood, doxycycline, and talc in a rabbit model.

Authors:  R E Mitchem; B L Herndon; R M Fiorella; A Molteni; C N Battie; G R Reisz
Journal:  Ann Thorac Surg       Date:  1999-04       Impact factor: 4.330

3.  Systemic absorption of tetracycline and lidocaine following intrapleural instillation.

Authors:  S A Wooten; R A Barbarash; C Strange; S A Sahn
Journal:  Chest       Date:  1988-11       Impact factor: 9.410

4.  Early inflammatory response of minocycline and tetracycline on the rabbit pleura.

Authors:  S R Dryzer; J Joseph; M Baumann; K Birmingham; S A Sahn; C Strange
Journal:  Chest       Date:  1993-11       Impact factor: 9.410

Review 5.  Chemical pleurodesis for malignant pleural effusions.

Authors:  P B Walker-Renard; L M Vaughan; S A Sahn
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

6.  Histologic changes of doxycycline pleurodesis in rabbits. Effect of concentration and pH.

Authors:  A N Hurewitz; K Lidonicci; C L Wu; D Reim; S Zucker
Journal:  Chest       Date:  1994-10       Impact factor: 9.410

7.  Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease.

Authors:  C Strange; M H Baumann; S A Sahn; S Idell
Journal:  Am J Respir Crit Care Med       Date:  1995-02       Impact factor: 21.405

8.  The efficacy of polidocanol in pleurodesis in rats.

Authors:  Bahadir Cetin; E Arzu Koçkaya; Can Atalay; M Turan Akay; Abdullah Cetin
Journal:  Surg Today       Date:  2003       Impact factor: 2.549

9.  The intrapleural administration of recombinant interleukin-2 (rIL-2) to patients with malignant pleural effusion: clinical trials.

Authors:  H Suzuki; S Abo; M Kitamura; M Hashimoto; K Izumi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

10.  Comparison of the effectiveness of tetracycline and minocycline as pleural sclerosing agents in rabbits.

Authors:  R W Light; N S Wang; C S Sassoon; S E Gruer; F S Vargas
Journal:  Chest       Date:  1994-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.